Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.32 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011462 | 0.88 | KMT2A (0.42) | USP2ALDH1A1MAPK1APEX1LMNA | |
| SCHEMBL27381966 | 0.81 | GAA (0.37) | USP2ALDH1A1MAPK1ATMPLA2G4A | |
| Bromide SCHEMBL5563404 | 0.74 | GAA (0.35) | ALDH1A1GAA | |
| SCHEMBL27784187 | 0.65 | VEGFA (0.43) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL27994026 | 0.65 | VEGFA (0.43) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL17870725 | 0.64 | GAA (0.47) | GAAAPEX1SLC6A9KDM4EKMT2A | |
| SCHEMBL10123555 | 0.64 | ALDH1A1 (0.40) | ALDH1A1APEX1LMNAKDM4EKMT2A | |
| SCHEMBL11538981 | 0.62 | GAA (0.43) | USP2ALDH1A1MAPK1GAALMNA | |
| SCHEMBL4427312 | 0.61 | ALDH1A1 (0.43) | ALDH1A1GAAAPEX1LMNAKDM4E | |
| SCHEMBL11335494 | 0.61 | CYP19A1 (0.40) | ALDH1A1LMNAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | USP2 4186/4885ALDH1A1 500/4885MAPK1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.